Jess Wiggs 8/14/20 Jess Wiggs 8/14/20 One Year Since U.S. Approval, Accelerating Access to New TB Therapy Read More Jess Wiggs 8/3/20 Jess Wiggs 8/3/20 TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis Read More Jess Wiggs 7/22/20 Jess Wiggs 7/22/20 Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis Read More Jess Wiggs 5/27/20 Jess Wiggs 5/27/20 TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen Read More Jess Wiggs 3/24/20 Jess Wiggs 3/24/20 COVID-19: a message of solidarity on World TB Day 2020 Read More Jess Wiggs 3/5/20 Jess Wiggs 3/5/20 Nix-TB Trial Results Published in New England Journal of Medicine Read More Jess Wiggs 1/27/20 Jess Wiggs 1/27/20 New Research Assesses Efficacy of Different Doses of Linezolid, Key Medicine Used in Regimens that Treat Drug-Resistant Tuberculosis Read More Jess Wiggs 1/16/20 Jess Wiggs 1/16/20 TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China Read More Jess Wiggs 10/28/19 Jess Wiggs 10/28/19 TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid Read More Jess Wiggs 10/28/19 Jess Wiggs 10/28/19 TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB Read More Jess Wiggs 4/18/19 Jess Wiggs 4/18/19 TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis Read More Newer Posts
Jess Wiggs 8/14/20 Jess Wiggs 8/14/20 One Year Since U.S. Approval, Accelerating Access to New TB Therapy Read More
Jess Wiggs 8/3/20 Jess Wiggs 8/3/20 TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis Read More
Jess Wiggs 7/22/20 Jess Wiggs 7/22/20 Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis Read More
Jess Wiggs 5/27/20 Jess Wiggs 5/27/20 TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen Read More
Jess Wiggs 3/24/20 Jess Wiggs 3/24/20 COVID-19: a message of solidarity on World TB Day 2020 Read More
Jess Wiggs 3/5/20 Jess Wiggs 3/5/20 Nix-TB Trial Results Published in New England Journal of Medicine Read More
Jess Wiggs 1/27/20 Jess Wiggs 1/27/20 New Research Assesses Efficacy of Different Doses of Linezolid, Key Medicine Used in Regimens that Treat Drug-Resistant Tuberculosis Read More
Jess Wiggs 1/16/20 Jess Wiggs 1/16/20 TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China Read More
Jess Wiggs 10/28/19 Jess Wiggs 10/28/19 TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid Read More
Jess Wiggs 10/28/19 Jess Wiggs 10/28/19 TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB Read More
Jess Wiggs 4/18/19 Jess Wiggs 4/18/19 TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis Read More